PP2A-β Inhibitors

Chemical inhibitors of protein phosphatase 2A (PP2A-β) utilize various mechanisms to impede its function. Okadaic Acid, for instance, is known for its strong inhibition of PP2A-β by binding directly to the catalytic subunit. This binding hinders the dephosphorylation of substrates, maintaining a state of sustained phosphorylation within the cell. Similarly, Calyculin A interacts with PP2A-β's catalytic site, which results in proteins remaining phosphorylated due to the blockade of the phosphatase's activity. Tautomycin, on the other hand, achieves selectivity by attaching to the phosphatase domain of PP2A-β, thus forestalling its activity. This action leads to an increase in phosphorylated proteins, as the enzyme's ability to dephosphorylate its substrates is inhibited.

Other inhibitors, such as Cantharidin and Microcystin-LR, covalently modify the catalytic subunit of PP2A-β. Cantharidin does so, resulting in an accumulation of phosphorylated proteins, while Microcystin-LR's binding similarly inhibits the enzyme's activity, leading to hyperphosphorylation. Endothall mimics the transition state of dephosphorylation and binds to the catalytic site of PP2A-β, which prevents substrate access and inhibits the enzymatic process. Fostriecin also targets the active site of PP2A-β, thereby blocking substrate access and inhibiting phosphatase activity. Phenylarsine Oxide interacts with vicinal dithiols within the catalytic subunit, thereby inhibiting the dephosphorylation function of PP2A-β. Some inhibitors such as Ionomycin and Demecolcine indirectly inhibit PP2A-β; Ionomycin increases intracellular calcium levels that can affect PP2A-β activity, while Demecolcine disrupts microtubule polymerization, which can indirectly influence PP2A-β signaling and function. Cylindrospermopsin and Nodularin also bind to the active site of PP2A-β, preventing dephosphorylation of substrates and disrupting cellular signaling processes.